|
LIVINGSTON HEALTHCARE AND LIFE SCIENCE STAKEHOLDERS SUMMIT
Capturing Trends and Global Outlook: Advanced and Emerging Technologies
September 24, 2009 - 12:00-5:00pm
New York, NY 10036
- CONFERENCE CHAIR: Mostafa Analoui, PhD, Head of Healthcare and Life Sciences
EVENT DIRECTOR: Jonathan Mason, jonathan@livingstonsecurities.com, 212-520-8479
- OVERVIEW AND OBJECTIVES
This is a unique and by invitation-only conference to bring together key stakeholders from pharmaceutical, capital investment, business strategy and federal science and regulatory segments. Conference will include three topics, which are among top global issues for investors currently. Attendance in the conference is intended to be limited to assure open and interactive dialogue among participants during the sessions and networking breaks. This is intended to collectively identify key trends, as well as mutual opportunities among participants for deal making.
- PROGRAM OUTLINE
- INTRODUCTION: Overview and key investment indicators
- SESSION I: Drug Discovery and Development: Early to Mid- Stage Fund Raise and Alliance
· Major Pharma
· Small/Emerging company view
· VC/PE
- SESSION II: Diagnostics: Valuation and Future Directions
· Current Landscape
· Business/technology and finance
· Key future directions
- SESSION III: Global and Emerging Investment Opportunities
· Overview and key players
· SPAC and Healthcare
· Global VCs and PEs
- NETWORKING RECEPTION
Invitees include CEOs, CFOs, COOs for a broad range of pharmaceutical, diagnostic, and platform technology companies, a select number of US and International VCs and PEs, along with key policy makers and federal science and regulatory agencies.
- CONFIRMED PANELLISTS
- BJ Bormann, PhD, VP of Business Development, Boehringer Ingelheim Pharmaceuticals
Bill Burkoth, Director of Venture Capital, Pfizer Inc
Mike Krams, MD, VP of Clinical, Wyeth
Alex Engels, VP of International Strategy, Baxter
David Collier, MD, Managing Director, CMEA Venture
Katherine Holland, General Manger, IBM Global Life sciences
Michael Nowak, PhD, Yorkville Partners
Misty Ushio, PhD, VP of Harris & Harris Venture
Richard Franks, MD, PhD, VP Medical Affairs and Clinical Strategy, GE Healthcare
Amit Kulkarni, PhD, Chemical Nanotechnology, GE Global Research
Gary Fletcher, PhD, Technology R&D, Becton-Dickenson (BD) Diagnostics
Douglas Fambrough, MD, Managing Partner, Oxford Bioscience Partners
Frank Lin, PhD, EuclidSR Venture
Jonathan White , MD, Head of R&D at Haemonetics
Ben Schrag, PhD, NSF, TBC
Barry Heavey, IDA Ireland, TBD
De Souza Christopher, PhD, VP of Bus Dev Skyepharma
Wendy Sanhai, FDA, tentative
Amar Sharma, PhD, aVP of Clinical, Wyeth
Eugene Seymour, MD, CEO of Nanoviricides, Inc
Camilla khevenhueller Borghese, President of ibi, Rome, Italy
Giannis Tomazos, PhD, CEO of Biorasis
|
